SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

05 May 2023 Evaluate
A fair growth of 17.20% in the revenue at Rs. 1194.06 millions was reported in the March 2023 quarter as compared to Rs. 1018.80 millions during year-ago period.The Company's Net profit for the March 2023 quarter have declined marginally to Rs. 161.54  millions as against Rs. 188.87 millions reported during the corresponding quarter ended.The company reported a degrowth in operating Profit to 161.86 millions from 232.91 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1194.06 1018.80 17.20 4030.44 4278.11 -5.79 4030.44 4278.11 -5.79
Other Income 7.83 11.92 -34.31 56.78 106.29 -46.58 56.78 106.29 -46.58
PBIDT 161.86 232.91 -30.51 603.56 1163.97 -48.15 603.56 1163.97 -48.15
Interest 31.79 11.81 169.18 83.84 49.51 69.34 83.84 49.51 69.34
PBDT 94.20 221.10 -57.39 483.85 1114.46 -56.58 483.85 1114.46 -56.58
Depreciation 25.30 21.47 17.84 95.54 81.80 16.80 95.54 81.80 16.80
PBT 68.90 199.63 -65.49 388.31 1032.66 -62.40 388.31 1032.66 -62.40
TAX -92.64 10.76 -960.97 -16.34 72.79 -122.45 -16.34 72.79 -122.45
Deferred Tax -48.04 -24.23 98.27 -35.93 -107.29 -66.51 -35.93 -107.29 -66.51
PAT 161.54 188.87 -14.47 404.65 959.87 -57.84 404.65 959.87 -57.84
Equity 221.65 221.65 0.00 221.65 221.65 0.00 221.65 221.65 0.00
PBIDTM(%) 13.56 22.86 -40.71 14.98 27.21 -44.96 14.98 27.21 -44.96

Tatva Chintan Pharma Share Price

1294.00 18.90 (1.48%)
20-Apr-2026 12:02 View Price Chart
Peers
Company Name CMP
BASF India 3700.00
Tata Chemicals 708.00
SRF 2490.00
Pidilite Inds. 1398.60
Deepak Nitrite 1536.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×